Shandong Sito Bio-technology Past Earnings Performance
Past criteria checks 1/6
Shandong Sito Bio-technology has been growing earnings at an average annual rate of 3.9%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 7.4% per year. Shandong Sito Bio-technology's return on equity is 1.7%, and it has net margins of 2.8%.
Key information
3.9%
Earnings growth rate
3.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 7.4% |
| Return on equity | 1.7% |
| Net Margin | 2.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Shandong Sito Bio-technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,189 | 33 | 140 | 55 |
| 31 Dec 23 | 1,280 | 46 | 144 | 55 |
| 30 Sep 23 | 1,302 | 62 | 137 | 60 |
| 30 Jun 23 | 1,340 | 70 | 132 | 58 |
| 31 Mar 23 | 1,393 | 45 | 130 | 57 |
| 31 Dec 22 | 1,312 | 42 | 127 | 50 |
| 30 Sep 22 | 1,253 | 46 | 128 | 47 |
| 30 Jun 22 | 1,215 | 50 | 121 | 44 |
| 31 Mar 22 | 1,184 | 54 | 124 | 46 |
| 01 Jan 22 | 1,203 | 36 | 125 | 50 |
| 30 Sep 21 | 1,070 | -99 | 129 | 54 |
| 30 Jun 21 | 1,044 | -124 | 133 | 54 |
| 31 Mar 21 | 963 | -161 | 122 | 49 |
| 31 Dec 20 | 913 | -180 | 130 | 45 |
| 30 Sep 20 | 904 | -77 | 133 | 50 |
| 30 Jun 20 | 879 | -45 | 122 | 53 |
| 31 Mar 20 | 901 | -1 | 114 | 57 |
| 31 Dec 19 | 966 | 55 | 86 | 56 |
| 30 Sep 19 | 992 | 110 | 85 | 35 |
| 30 Jun 19 | 1,071 | 120 | 75 | 30 |
| 31 Mar 19 | 1,099 | 129 | 76 | 39 |
| 31 Dec 18 | 1,052 | 126 | 76 | 39 |
| 30 Sep 18 | 1,129 | 146 | 70 | 49 |
| 30 Jun 18 | 1,040 | 134 | 59 | 60 |
| 31 Mar 18 | 923 | 117 | 61 | 38 |
| 31 Dec 17 | 786 | 92 | 54 | 32 |
| 30 Sep 17 | 690 | 74 | 46 | 17 |
| 30 Jun 17 | 611 | 76 | 62 | 0 |
| 31 Mar 17 | 624 | 99 | 55 | 0 |
| 31 Dec 16 | 568 | 101 | 55 | 0 |
| 30 Sep 16 | 562 | 115 | 100 | 0 |
| 31 Dec 15 | 668 | 187 | 56 | 0 |
| 31 Dec 14 | 521 | 166 | 35 | 0 |
| 31 Dec 13 | 284 | 42 | 18 | 0 |
Quality Earnings: 300583 has a large one-off loss of CN¥14.8M impacting its last 12 months of financial results to 31st March, 2024.
Growing Profit Margin: 300583's current net profit margins (2.8%) are lower than last year (3.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300583's earnings have grown by 3.9% per year over the past 5 years.
Accelerating Growth: 300583's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300583 had negative earnings growth (-25.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 300583's Return on Equity (1.7%) is considered low.